Abstract:A dual-response (near-infrared, alternating magnetic field) multifunctional nanoplatform was developed based on urokinase plasminogen activators (uPA)-loaded metal–organic-framework (MOF)-derived carbon nanomaterials (referred to below) for thrombolytic therapy. uPA loaded in mesoporous CFs could be released under the action of near-infrared (NIR)-mediated photothermy to achieve superficial thrombolysis. More importantly, with the assistance of alternating magnetic field (AMF), this system could also precisely heat the thrombosis in the deep tissue area. Quantitative experiments proved that the thrombolytic efficiency of this dual-response system at deep venous thrombosis was nearly 6 times than that of NIR alone. This is the first application that MOF-derived carbon nanomaterials in the field of targeted thrombolysis. To our delight, the MOF-derived carbon nanomaterials (CFs) not only maintained the drug-carrying capacity, but also endowed CFs with reliable magnetic targeting ability. More encouragingly, the CFs also showed extraordinary angiogenic performance, thus opening up the prospect of its clinical application.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.1c03134?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.1c03134</a>.Particle size distribution of CFs (Figure S1a). Stability of the CFs hydrodynamic size during different incubation periods with serum (Figure S1b). High-resolution XPS spectra of (a) Fe 2p, (b) O 1s, and (c) C 1s (Figure S2). The summary of nitrogen adsorption–desorption analysis of MOFs (Fe) and CFs samples (Table S1). Pore size distribution of (a) MOFs (Fe) and (b) CFs samples (Figure S3). VSM curve of at room temperature (Figure S4). The photothermal effect and magnetothermal effect of CFs (Figure S5). uPA release from after being placed in saline over 7 days (Figure S6). The thickness of pork (Figure S7a). Deep evaluation of the magnetic field attracting CFs using different thickness of pork (scale bar = 1 cm) (Figure S7b). SEM analysis of thrombolysis (scale bar = 2 μm) (Figure S8). Scanning electron microscopy (SEM) images and the elemental mapping data of the degradation of CFs at the thrombus site at (a) 20 min, (b) 40 min, and (c) 1 h (scale bar = 5 μm) (Figure S9). SEM images of RBCs treated with different concentrations of CFs (scale bar = 5 μm) (Figure S10). Cell viability of HSF and HUVECs treated with different concentrations of CFs for 24 h (Figure S11a). Cell viability with various concentrations of CFs, CFs + NIR, CFs + AMF for 12 and 48 h (Figure S11b). Cell viability of HUVECs cocultured with different concentrations of CFs and VEGF for various time as indicated above. (Error bars represent the standard deviation of six separate measurements) (Figure S12). Photos (clots are marked in blue circles, scale bar = 1 cm) of clots before and after treatment for 24 h (Figure S13). The amount of Fe in the major organs and blood after treatment for 7 days (Figure S14). Four indicators of coagulation in SD rats (Figure S15a). Some indexes of liver and kidney function in SD rats (Figure S15b). The average body weight of rats in each group during the treatment periods (Figure S16) (<a class="ext-link" href="/doi/suppl/10.1021/acsami.1c03134/suppl_file/am1c03134_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Gold-iron oxide nanoparticle: A unique multimodal theranostic approach for thrombosis

A Spiky Silver‐Iron Oxide Nanoparticle for Highly Efficient Targeted Photothermal Therapy and Multimodal Imaging of Thrombosis (Small 11/2023)

Thrombus-specific theranostic nanocomposite for codelivery of thrombolytic drug, algae-derived anticoagulant and NIR fluorescent contrast agent

Plasma‐Derived Nanoclusters for Site‐Specific Multimodality Photo/Magnetic Thrombus Theranostics

Thrombus-targeted nano-agents for NIR-II diagnostic fluorescence imaging-guided flap thromboembolism multi-model therapy

Dual-mode nanoprobe strategy integrating ultrasound and near-infrared light for targeted and synergistic arterial thrombolysis

Theranostic nanoparticles for the management of thrombosis

Targeting Nanomotor with Near‐Infrared/Ultrasound Triggered‐Transformation for Polystage‐Propelled Cascade Thrombolysis and Multimodal Imaging Diagnosis

Nano-Medicine for Thrombosis: A Precise Diagnosis and Treatment Strategy

Multi-enzyme mimetic iridium nanozymes-based thrombus microenvironment-modulated nanoplatform for enhanced thrombolytic therapy

H2O2-triggered "off/on signal" nanoparticles target P-selectin for the non-invasive and contrast-enhanced theranostics for arterial thrombosis

A multifunctional AIE gold cluster-based theranostic system: tumor-targeted imaging and Fenton reaction-assisted enhanced radiotherapy

Near-infrared-II photoacoustic imaging and photo-triggered synergistic treatment of thrombosis via fibrin-specific homopolymer nanoparticles

PET/NIRF/MRI triple functional iron oxide nanoparticles.

Construction and evaluation of Fe₃O₄-based PLGA nanoparticles carrying rtPA used in the detection of thrombosis and in targeted thrombolysis

Targeted Thrombolytic Therapy with Metal–Organic-Framework-Derived Carbon Based Platforms with Multimodal Capabilities

Rapid in Situ Biosynthesis of Gold Nanoparticles in Living Platelets for Multimodal Biomedical Imaging.

Peptide‐Enabled Thrombus‐Targeting Nanoparticles for Highly Effective Targeted CT Imaging and Eradication of Thrombi

Preparation and Evaluation of a Radioisotope-Incorporated Iron Oxide Core/Au Shell Nanoplatform for Dual Modality Imaging

Upconversion nanoparticles regulated drug & gas dual-effective nanoplatform for the targeting cooperated therapy of thrombus and anticoagulation

pH-Responsive theranostic colloidosome drug carriers enable real-time imaging of targeted thrombolytic process with near-infrared-II for deep venous thrombosis